CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR 竞速兽医免疫肿瘤学
英文原题：Racing CARs to veterinary immuno-oncology.
查看英文原题
Racing CARs to veterinary immuno-oncology.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去20年间，嵌合抗原受体（CAR）在人类肿瘤学领域展现出显著前景，但兽医学中的类似策略仍处于开发阶段。CAR是人工工程化蛋白，由特异性抗原结合单链可变片段（scFv）与T细胞受体及共受体的信号结构域融合构成。经工程化改造表达CAR的患者T细胞，可被引导识别并杀伤靶细胞，靶细胞最常见为血液系统恶性肿瘤细胞。美国食品药品监督管理局（FDA）已批准多种人用CAR-T 疗法，但将这些疗法转化为兽医治疗面临诸多挑战。本综述讨论兽医应用的相关考量，包括CAR设计和细胞载体选择，并探讨CAR疗法应用于兽医肿瘤学的未来前景。
展开英文摘要原文
Chimeric antigen receptors (CARs) have demonstrated remarkable promise in human oncology over the past two decades, yet similar strategies in veterinary medicine are still in development. CARs are synthetically engineered proteins comprised of a specific antigen-binding single chain variable fragment (ScFv) fused to the signaling domain of a T cell receptor and co-receptors.
Patient T cells engineered to express a CAR are directed to recognize and kill target cells, most commonly hematological malignancies. The U. S Food and Drug Administration (FDA) has approved multiple human CAR T therapies, but translation of these therapies into veterinary medicine faces many challenges. In this review, we discuss considerations for veterinary use including CAR design and cell carrier choice, and discuss the future promise of translating CAR therapy into veterinary oncology.
论文信息
- 作者
- Cockey JR、Leifer CA
- 单位
- Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States.United States
- 文献类型
- 综述
- 期刊
- Frontiers in veterinary science2023
- 原文标识
- PubMed 36876006 · DOI 10.3389/fvets.2023.1130182
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →